Getting your Trinity Audio player ready...

In July 2024, Intelligent Bio Solutions Inc. (Nasdaq: INBS) revealed that three UK-based manufacturers adopted its Fingerprint Drug Screening System, renowned for its fast, intelligent, and non-invasive drug detection through fingertip sweat. This innovation’s biocompatibility has propelled it towards FDA clearance, with plans for a U.S. launch in 2025.

On August 1, Intelligent Bio Solutions entered a strategic partnership with CenExel, a nationwide clinical research site network operator. This collaboration is part of an FDA clinical study plan, involving a method comparison clinical study.

Under the study, 135 healthy adult subjects across three sites will participate in tests comparing the fingerprint sweat opiate screening results with those from the traceable LC-MS/MS method, the current gold standard.

This partnership and study are the final stages of Intelligent Bio Solutions’ clinical study plan. Over the past two months, the company has made significant progress and is on track to submit its 510(k) application to the FDA in Q4 2024. The company praised the efforts of its clinical study partners and team for their role in the smooth progression of this process.

Intelligent Bio Solutions Inc. is moving closer to revolutionizing drug screening with its innovative, non-invasive solutions.

Here are four healthcare companies under $10 demonstrating robust market trends, volume, and awareness:

  1. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) – Focuses on therapies for central nervous system disorders.
  2. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) – Specializes in cancer immunotherapy products.
  3. Savara Inc. (NASDAQ: SVRA) – Develops therapies for rare respiratory diseases.
  4. Eyenovia, Inc. (NASDAQ: EYEN) – Innovates in ophthalmic treatments.

These companies are actively involved in the healthcare sector, showcasing market strength through their innovative products and services.